Sex bias in systemic lupus erythematosus: a molecular insight-Immunometabolism-CSCIED科技核心评价数据库-手机版

Sex bias in systemic lupus erythematosus: a molecular insight

Sex bias in systemic lupus erythematosus: a molecular insight

ES评分 0 浏览量：1095 下载量：2

DOI	10.1097/IN9.0000000000000004
刊名	Immunometabolism IJ
年，卷(期)	2022, 4(3)
作者	Bose, Moumita; Jefferies, Caroline,
作者单位	[Bose, Moumita; Jefferies, Caroline] Cedars Sinai Med Ctr, Dept Med, Div Rheumatol, Los Angeles, CA 90048 USA; [Bose, Moumita; Jefferies, Caroline] Cedars Sinai Med Ctr, Dept Biomed Sci, Res Div Immunol, Los Angeles, CA 90048 USA
摘要	Acknowledging sex differences in immune response is particularly important when we consider the differences between men and women in the incidence of disease. For example, over 80% of autoimmune disease occurs in women, whereas men have a higher incidence of solid tumors compared to women. In general women have stronger innate and adaptive immune responses than men, explaining their ability to clear viral and bacterial infections faster, but also contributing to their increased susceptibility to autoimmune disease. The autoimmune disease systemic lupus erythematosus (SLE) is the archetypical sexually dimorphic disease, with 90% of patients being women. Various mechanisms have been suggested to account for the female prevalence of SLE, including sex hormones, X-linked genes, and epigenetic regulation of gene expression. Here, we will discuss how these mechanisms contribute to pathobiology of SLE and how type I interferons work with them to augment sex specific disease pathogenesis in SLE.
Abstract	Acknowledging sex differences in immune response is particularly important when we consider the differences between men and women in the incidence of disease. For example, over 80% of autoimmune disease occurs in women, whereas men have a higher incidence of solid tumors compared to women. In general women have stronger innate and adaptive immune responses than men, explaining their ability to clear viral and bacterial infections faster, but also contributing to their increased susceptibility to autoimmune disease. The autoimmune disease systemic lupus erythematosus (SLE) is the archetypical sexually dimorphic disease, with 90% of patients being women. Various mechanisms have been suggested to account for the female prevalence of SLE, including sex hormones, X-linked genes, and epigenetic regulation of gene expression. Here, we will discuss how these mechanisms contribute to pathobiology of SLE and how type I interferons work with them to augment sex specific disease pathogenesis in SLE.
关键词	SLE; sex disparities; inflammation; estrogen; IFN alpha; X chromosome dosage; epigenetics; mitochondria
KeyWord	SLE; sex disparities; inflammation; estrogen; IFN alpha; X chromosome dosage; epigenetics; mitochondria
基金项目
页码	1-6

参考文献
相关文献

[1]. Danchenko N, Satia JA, Anthony MS. Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus. 2006;15:308–18.

[2]. Klein SL, Flanagan KL. Sex differences in immune responses. Nat Rev Immunol. 2016;16:6268.

[3]. McMurray RW, May W. Sex hormones and systemic lupus erythematosus: review and meta-analysis. Arthritis Rheum. 2003;48:2100–10.

[4]. Parks RJ, Ray G, Bienvenu LA, et al. Sex differences in SR Ca(2+) release in murine ventricular myocytes are regulated by the cAMP/PKA pathway. J Mol Cell Cardiol. 2014;75:162–73.

[5]. Kaul A, Gordon C, Crow MK, et al. Systemic lupus erythematosus. Nat Rev Dis Primers. 2016;2:16039.

[6]. Kim HI, Lim H, Moon A. Sex differences in cancer: epidemiology, genetics and therapy. Biomol Ther. 2018;26:335–42.

[7]. Rubtsova K, Marrack P, Rubtsov AV. Sexual dimorphism in autoimmunity. J Clin Invest. 2015;125:2187–93.

[8]. Moulton VR. Sex hormones in acquired immunity and autoimmune disease. Front Immunol. 2018;9:2279.

[9]. Ortona E, Pierdominici M, Rider V. Editorial: sex hormones and gender differences in immune responses. Front Immunol. 2019;10:1076.

[10]. Ngo ST, Steyn FJ, McCombe PA. Gender differences in autoimmune disease. Front Neuroendocrinol. 2014;35:347–69.

[11]. Gubbels Bupp MR, Jorgensen TN. Androgen-induced immunosuppression. Front Immunol. 2018;9:794.

[12]. Shah R, Newcomb DC. Sex bias in asthma prevalence and pathogenesis. Front Immunol. 2018;9:2997.

[13]. Barker DJ, Eriksson JG, Forsen T, et al. Fetal origins of adult disease: strength of effects and biological basis. Int J Epidemiol. 2002;31:1235–9.

[14]. Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;53:487–95.

[15]. Meier A, Chang JJ, Chan ES, et al. Sex differences in the Toll-like receptor–mediated response of plasmacytoid dendritic cells to HIV-1. Nat Med. 2009;15:955–9.

[16]. Griesbeck M, Ziegler S, Laffont S, et al. Sex differences in plasmacytoid dendritic cell levels of IRF5 drive higher IFN-α production in women. J Immunol. 2015;195:5327–36.

[17]. Laffont S, Rouquié N, Azar P, et al. X-chromosome complement and estrogen receptor signaling independently contribute to the enhanced TLR7-mediated IFN-α production of plasmacytoid dendritic cells from women. J Immunol. 2014;193:5444–52.

[18]. Seillet C, Laffont S, Trémollières F, et al. The TLR-mediated response of plasmacytoid dendritic cells is positively regulated by estradiol in vivo through cell-intrinsic estrogen receptor α signaling. Blood. 2012;119:454–64.

[19]. Ronnblom L. The importance of the type I interferon system in autoimmunity. Clin Exp Rheumatol. 2016;34(4 Suppl 98):21–4.

[20]. Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease. Annu Rev Pathol. 2019;14:369–93.

[21]. Postal M, Vivaldo JF, Fernandez-Ruiz R, et al. Type I interferon in the pathogenesis of systemic lupus erythematosus. Curr Opin Immunol. 2020;67:87–94.

[22]. McWhirter SM, Jefferies CA. Nucleic acid sensors as therapeutic targets for human disease. Immunity. 2020;53:78–97.

[23]. Hagiwara AM, Moore RE, Wallace DJ, et al. Regulation of cGAS-STING pathway-implications for systemic lupus erythematosus. J Rheumatol Immunol Res. 2021;2:173–84.

[24]. Celhar T, Fairhurst AM. Toll-like receptors in systemic lupus erythematosus: potential for personalized treatment. Front Pharmacol. 2014;5:265.

[25]. Singh RP, Hahn BH, Bischoff DS. Interferon genes are influenced by 17β-estradiol in SLE. Front Immunol. 2021;12:725325.

[26]. Tsokos GC. Systemic lupus erythematosus. N Engl J Med. 2011;365:2110–21.

[27]. Tedeschi SK, Bermas B, Costenbader KH. Sexual disparities in the incidence and course of SLE and RA. Clin Immunol. 2013;149:211–8.

[28]. Lu LJ, Wallace DJ, Ishimori ML, et al. Review: male systemic lupus erythematosus: a review of sex disparities in this disease. Lupus. 2010;19:119–29.

[29]. Hill BG, Hodge B, Misischia R. Lupus nephritis in a transgender woman on cross-sex hormone therapy: a case for the role of oestrogen in systemic lupus erythematosus. Lupus. 2020;29:1807–10.

[30]. Michalski JP, McCombs CC, Roubinian JR, et al. Effect of androgen therapy on survival and suppressor cell activity in aged NZB/NZW F1 hybrid mice. Clin Exp Immunol. 1983;52:229–33.

[31]. Roubinian JR, Talal N, Greenspan JS, et al. Delayed androgen treatment prolongs survival in murine lupus. J Clin Invest. 1979;63:902–11.

[32]. Roubinian JR, Papoian R, Talal N. Androgenic hormones modulate autoantibody responses and improve survival in murine lupus. J Clin Invest. 1977;59:1066–70.

[33]. Roubinian JR, Talal N, Greenspan JS, et al. Effect of castration and sex hormone treatment on survival, anti-nucleic acid antibodies, and glomerulonephritis in NZB/NZW F1 mice. J Exp Med. 1978;147:1568–83.

[34]. Sthoeger ZM, Zinger H, Mozes E. Beneficial effects of the anti-oestrogen tamoxifen on systemic lupus erythematosus of (NZBxNZW)F1 female mice are associated with specific reduction of IgG3 autoantibodies. Ann Rheum Dis. 2003;62:341–6.

[35]. Tabor DE, Gould KA. Estrogen receptor alpha promotes lupus in (NZB×NZW)F1 mice in a B cell intrinsic manner. Clin Immunol. 2017;174:41–52.

[36]. Rojas-Villarraga A, Torres-Gonzalez JV, Ruiz-Sternberg AM. Safety of hormonal replacement therapy and oral contraceptives in systemic lupus erythematosus: a systematic review and meta-analysis. PLoS One. 2014;9:e104303.

[37]. Smith S, Gabhann JN, McCarthy E, et al. Estrogen receptor α regulates tripartite motif-containing protein 21 expression, contributing to dysregulated cytokine production in systemic lupus erythematosus. Arthritis Rheumatol. 2014;66:163–72.

[38]. Panchanathan R, Shen H, Zhang X, et al. Mutually positive regulatory feedback loop between interferons and estrogen receptor-alpha in mice: implications for sex bias in autoimmunity. PLoS One. 2010;5:e10868.

[39]. Olsen NJ, Benko AL, Kovacs WJ. Variation in the androgen receptor gene exon 1 CAG repeat correlates with manifestations of autoimmunity in women with lupus. J Endocr Connect. 2014;3:99–109.

[40]. Tessnow A, Olsen N, Kovacs W. Expression of humoral autoimmunity is related to androgen receptor CAG repeat length in men with systemic lupus erythematosus. J Clin Immunol. 2011;31:567–73.

[41]. Svenson JL, EuDaly J, Ruiz P, et al. Impact of estrogen receptor deficiency on disease expression in the NZM2410 lupus prone mouse. Clin Immunol. 2008;128:259–68.

[42]. Perry DJ, Yin Y, Telarico T, et al. Murine lupus susceptibility locus Sle1c2 mediates CD4+ T cell activation and maps to estrogen-related receptor gamma. J Immunol. 2012;189:793–803.

[43]. Kassi E, Moutsatsou P. Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus. J Biomed Biotechnol. 2010;2010:317452.

[44]. Hui-Yuen JS, Christiano AM, Askanase A. Sex differences in genomics in lupus: girls with systemic lupus have high interferon gene expression while boys have high levels of tumour necrosis factor-related gene expression. Scand J Rheumatol. 2016;45:394–6.

[45]. Byrne JC, Ni Gabhann J, Lazzari E, et al. Genetics of SLE: functional relevance for monocytes/macrophages in disease. Clin Dev Immunol. 2012;2012:582352.

[46]. Grimaldi CM, Cleary J, Dagtas AS, et al. Estrogen alters thresholds for B cell apoptosis and activation. J Clin Invest. 2002;109:1625–33.

[47]. Grimaldi CM, Hill L, Xu X, et al. Hormonal modulation of B cell development and repertoire selection. Mol Immunol. 2005;42:811–20.

[48]. Hill L, Jeganathan V, Chinnasamy P, et al. Differential roles of estrogen receptors α and β in control of B-cell maturation and selection. Mol Med. 2011;17:211–20.

[49]. Mousavi MJ, Mahmoudi M, Ghotloo S. Escape from X chromosome inactivation and female bias of autoimmune diseases. Mol Med. 2020;26:127.

[50]. Scofield RH, Bruner GR, Namjou B, et al. Klinefelter’s syndrome (47,XXY) in male systemic lupus erythematosus patients: support for the notion of a gene-dose effect from the X chromosome. Arthritis Rheum. 2008;58:2511–7.

[51]. Cooney CM, Bruner GR, Aberle T, et al. 46,X,del(X)(q13) Turner’s syndrome women with systemic lupus erythematosus in a pedigree multiplex for SLE. Genes Immun. 2009;10:478–81.

[52]. Cotton AM, Price EM, Jones MJ, et al. Landscape of DNA methylation on the X chromosome reflects CpG density, functional chromatin state and X-chromosome inactivation. Hum Mol Genet. 2015;24:1528–39.

[53]. Kalantry S. Recent advances in X-chromosome inactivation. J Cell Physiol. 2011;226:1714–8.

[54]. Syrett CM, Paneru B, Sandoval-Heglund D, et al. Altered X-chromosome inactivation in T cells may promote sex-biased autoimmune diseases. JCI Insight. 2019;4:127.

[55]. Disteche CM, Berletch JB. X-chromosome inactivation and escape. J Genet. 2015;94:591–9.

[56]. Youness A, Miquel CH, Guéry JC. Escape from X chromosome inactivation and the female predominance in autoimmune diseases. Int J Mol Sci. 2021;22:1114.

[57]. Kay GF, Penny GD, Patel D, et al. Expression of Xist during mouse development suggests a role in the initiation of X chromosome inactivation. Cell. 1993;72:171–82.

[58]. Bianchi I, Lleo A, Gershwin ME, et al. The X chromosome and immune associated genes. J Autoimmun. 2012;38:J187–92.

[59]. Hewagama A, Gorelik G, Patel D, et al. Overexpression of X-linked genes in T cells from women with lupus. J Autoimmun. 2013;41:60–71.

[60]. Lu Q, Wu A, Tesmer L, et al. Demethylation of CD40LG on the inactive X in T cells from women with lupus. J Immunol. 2007;179:6352–8.

[61]. Souyris M, Cenac C, Azar P, et al. TLR7 escapes X chromosome inactivation in immune cells. Sci Immunol. 2018;3:eaap8855.

[62]. Umiker BR, Andersson S, Fernandez L, et al. Dosage of X-linked Toll-like receptor 8 determines gender differences in the development of systemic lupus erythematosus. Eur J Immunol. 2014;44:1503–16.

[63]. Greenfield A, Carrel L, Pennisi D, et al. The UTX gene escapes X inactivation in mice and humans. Hum Mol Genet. 1998;7:737–42.

[64]. Gažová I, Lengeling A, Summers KM. Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation. Mol Genet Metab. 2019;127:31–44.

[65]. Itoh Y, Golden LC, Itoh N, et al. The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity. J Clin Invest. 2019;129:3852–63.

[66]. Hurtado C, Acevedo Sáenz LY, Vásquez Trespalacios EM, et al. DNA methylation changes on immune cells in systemic lupus erythematosus. Autoimmunity. 2020;53:114–21.

[67]. Jeffries MA, Sawalha AH. Epigenetics in systemic lupus erythematosus: leading the way for specific therapeutic agents. Int J Clin Rheumtol. 2011;6:423–39.

[68]. Scharer CD, Blalock EL, Mi T, et al. Epigenetic programming underpins B cell dysfunction in human SLE. Nat Immunol. 2019;20:1071–82.

[69]. Breitbach ME, Ramaker RC, Roberts K, et al. Population-specific patterns of epigenetic defects in the B cell lineage in patients with systemic lupus erythematosus. Arthritis Rheumatol. 2020;72:282–91.

[70]. Adams DE, Shao WH. Epigenetic alterations in immune cells of systemic lupus erythematosus and therapeutic implications. Cells. 2022;11:506.

[71]. Tanaka S, Ise W, Inoue T, et al. Tet2 and Tet3 in B cells are required to repress CD86 and prevent autoimmunity. Nat Immunol. 2020;21:950–61.

[72]. Gujral P, Mahajan V, Lissaman AC, et al. Histone acetylation and the role of histone deacetylases in normal cyclic endometrium. Reprod Biol Endocrinol. 2020;18:84.

[73]. Jambhekar A, Dhall A, Shi Y. Roles and regulation of histone methylation in animal development. Nat Rev Mol Cell Biol. 2019;20:625–41.

[74]. Keiser AA, Wood MA. Examining the contribution of histone modification to sex differences in learning and memory. Learn Mem. 2019;26:318–31.

[75]. Gal-Oz ST, Maier B, Yoshida H, et al. ImmGen report: sexual dimorphism in the immune system transcriptome. Nat Commun. 2019;10:4295.

[76]. Hua C, Chen J, Li S, et al. KDM6 demethylases and their roles in human cancers. Front Oncol. 2021;11:779918.

[77]. Wu H, Chen Y, Zhu H, et al. The pathogenic role of dysregulated epigenetic modifications in autoimmune diseases. Front Immunol. 2019;10:2305.

[78]. Hedrich CM. Epigenetics in SLE. Curr Rheumatol Rep. 2017;19:58.

[79]. Hedrich CM, Rauen T, Tsokos GC. cAMP-responsive element modulator (CREM)alpha protein signaling mediates epigenetic remodeling of the human interleukin-2 gene: implications in systemic lupus erythematosus. J Biol Chem. 2011;286:43429–36.

[80]. Hedrich CM, Rauen T, Apostolidis SA, et al. Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci USA. 2014;111:13457–62.

[81]. Pinheiro I, Dejager L, Libert C. X-chromosome-located microRNAs in immunity: might they explain male/female differences? The X chromosome-genomic context may affect X-located miRNAs and downstream signaling, thereby contributing to the enhanced immune response of females. BioEssays. 2011;33:791–802.

[82]. Khalifa O, Pers YM, Ferreira R, et al. X-linked miRNAs Associated with gender differences in rheumatoid arthritis. Int J Mol Sci. 2016;17:1852.

[83]. Dai Y, Huang YS, Tang M, et al. Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus. 2007;16:939–46.

[84]. Dai Y, Sui W, Lan H, et al. Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatol Int. 2009;29:749–54.

[85]. Stagakis E, Bertsias G, Verginis P, et al. Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. Ann Rheum Dis. 2011;70:1496–506.

[86]. Zan H, Tat C, Casali P. MicroRNAs in lupus. Autoimmunity. 2014;47:272–85.

[87]. Chi M, Ma K, Li Y, et al. Immunological involvement of microRNAs in the key events of systemic lupus erythematosus. Front Immunol. 2021;12:699684.

[88]. Pan W, Zhu S, Yuan M, et al. MicroRNA-21 and microRNA-148a contribute to DNA hypomethylation in lupus CD4+ T cells by directly and indirectly targeting DNA methyltransferase 1. J Immunol. 2010;184:6773–81.

[89]. Tang Y, Luo X, Cui H, et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis Rheum. 2009;60:1065–75.

[90]. Smith S, Wu PW, Seo JJ, et al. IL-16/miR-125a axis controls neutrophil recruitment in pristane-induced lung inflammation. JCI Insight. 2018;3:e120798.

[91]. Smith S. MicroRNA-302d targets IRF9 to regulate the IFN-induced gene expression in SLE. J Autoimmun. 2017;79:105–11.

[92]. Leishangthem BD, Sharma A, Bhatnagar A. Role of altered mitochondria functions in the pathogenesis of systemic lupus erythematosus. Lupus. 2016;25:272–81.

[93]. Caza TN, Talaber G, Perl A. Metabolic regulation of organelle homeostasis in lupus T cells. Clin Immunol. 2012;144:200–13.

[94]. Yin Y, Choi SC, Xu Z, et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med. 2015;7:274ra18.

[95]. Ventura-Clapier R, Moulin M, Piquereau J, et al. Mitochondria: a central target for sex differences in pathologies. Clin Sci. 2017;131:803–22.

[96]. Sultanova RF, Schibalski R, Yankelevich IA, et al. Sex differences in renal mitochondrial function: a hormone-gous opportunity for research. Am J Physiol Renal Physiol. 2020;319:F1117–24.

[97]. Parkash J, Felty Q, Roy D. Estrogen exerts a spatial and temporal influence on reactive oxygen species generation that precedes calcium uptake in high-capacity mitochondria: implications for rapid nongenomic signaling of cell growth. Biochemistry. 2006;45:2872–81.

[98]. Silaidos C, Pilatus U, Grewal R, et al. Sex-associated differences in mitochondrial function in human peripheral blood mononuclear cells (PBMCs) and brain. Biol Sex Differ. 2018;9:34.

[99]. Klinge CM. Estrogenic control of mitochondrial function and biogenesis. J Cell Biochem. 2008;105:1342–51.

[100]. Hunt RJ, Bateman JM. Mitochondrial retrograde signaling in the nervous system. FEBS Lett. 2018;592:663–78.

[101]. Butow RA, Avadhani NG. Mitochondrial signaling: the retrograde response. Mol Cell. 2004;14:1–15.

[102]. Pyfrom S, Paneru B, Knox JJ, et al. The dynamic epigenetic regulation of the inactive X chromosome in healthy human B cells is dysregulated in lupus patients. Proc Natl Acad Sci USA. 2021;118:e2024624118.

引用本文

Bose, Moumita; Jefferies, Caroline. Sex bias in systemic lupus erythematosus: a molecular insight [J]. Immunometabolism. 2022; 4; (3). 1 - 6.

文献评论

相关学者

相关机构